Literature DB >> 15721120

Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes.

Josef Veselka1, Radka Duchonová, Sárka Procházková, Jana Pálenícková, Paul Sorajja, David Tesar.   

Abstract

This prospective, randomized study evaluates the association between ethanol dose and postprocedural hemodynamic changes in 42 patients treated by alcohol septal ablation for obstructive hypertrophic cardiomyopathy. These results suggest that the early course of hemodynamic changes is not related to the use of a small (1 to 2 ml) or standard (>2 ml) dose of ethanol.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15721120     DOI： 10.1016/j.amjcard.2004.10.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Charles J Knight
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

2.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

3.  How to Treat Obstructions in Patients with Hypertrophic Cardiomyopathy.

Authors:  Josef Veselka
Journal:  Int J Angiol       Date:  2015-06

4.  Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.

Authors:  Lothar Faber; Christian Prinz; Dirk Welge; Detlef Hering; Thomas Butz; Olaf Oldenburg; Nicola Bogunovic; Dieter Horstkotte
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-08       Impact factor: 2.357

5.  Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.

Authors:  Christian Sohns; Samuel Sossalla; Jan D Schmitto; Claudius Jacobshagen; Björn W Raab; Silvia Obenauer; Lars S Maier
Journal:  Clin Res Cardiol       Date:  2010-02-21       Impact factor: 5.460

6.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

7.  Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.

Authors:  Sammy Elmariah; Michael A Fifer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

8.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective.

Authors:  Josef Veselka; David Zemánek; Pavol Tomasov; Radka Duchonová; Katerina Linhartová
Journal:  Heart Vessels       Date:  2009-01-23       Impact factor: 2.037

9.  Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Jan Krejci; Pavel Gregor; David Zemanek; Klaudia Vyskocilova; Karol Curila; Radka Stepanova; Miroslav Novak; Ladislav Groch; Josef Veselka
Journal:  ScientificWorldJournal       Date:  2013-11-11

10.  Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.

Authors:  Josef Veselka; Lothar Faber; Max Liebregts; Robert Cooper; Jaroslav Januska; Jan Krejci; Thomas Bartel; Maciej Dabrowski; Peter Riis Hansen; Vibeke Marie Almaas; Hubert Seggewiss; Dieter Horstkotte; Radka Adlova; Henning Bundgaard; Jurriën Ten Berg; Rodney Hilton Stables; Morten Kvistholm Jensen
Journal:  J Am Heart Assoc       Date:  2017-05-16       Impact factor: 5.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.